Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Compton (2007)
Getting to personalized cancer medicineCancer, 110
Limei Yang, W. Ge, F. Yu, Huaijun Zhu (2010)
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.Thrombosis research, 125 4
M. Hillman, R. Wilke, M. Caldwell, R. Berg, I. Glurich, J. Burmester (2004)
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.Pharmacogenetics, 14 8
T. Geisler, E. Schaeffeler, J. Dippon, S. Winter, Verena Buse, C. Bischofs, C. Zuern, K. Moerike, M. Gawaz, M. Schwab (2008)
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Pharmacogenomics, 9 9
J. Hopewell, S. Parish, R. Clarke, J. Armitage, L. Bowman, J. Hager, M. Lathrop, R. Collins (2011)
No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.Journal of the American College of Cardiology, 57 20
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. Steg, J. Ferrières, N. Danchin, L. Becquemont, Abstr Act (2009)
Genetic determinants of response to clopidogrel and cardiovascular events.The New England journal of medicine, 360 4
C. Kearon, Jeffrey Ginsberg, M. Kovacs, D. Anderson, P. Wells, J. Julian, B. Mackinnon, J. Weitz, M. Crowther, S. Dolan, A. Turpie, W. Geerts, S. Solymoss, P. Nguyen, C. Demers, S. Kahn, J. Kassis, M. Rodger, J. Hambleton, M. Gent (2003)
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.The New England journal of medicine, 349 7
A. Rettie, L. Wienkers, F. Gonzalez, W. Trager, K. Korzekwa (1994)
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.Pharmacogenetics, 4 1
J. Lindh, Lennart Holm, M. Andersson, A. Rane (2009)
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology, 65
P. Staritz, K. Kurz, M. Stoll, E. Giannitsis, H. Katus, B. Ivandic (2009)
Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.International journal of cardiology, 133 3
Kate O'Dell, Daniel Igawa, Jerline Hsin (2012)
New oral anticoagulants for atrial fibrillation: a review of clinical trials.Clinical therapeutics, 34 4
A. Marian (2005)
Pharmacogenetic study of statin therapy and cholesterol reduction.Current atherosclerosis reports, 7 3
D. Cain, S. Hutson, R. Wallin (1997)
Assembly of the Warfarin-sensitive Vitamin K 2,3-Epoxide Reductase Enzyme Complex in the Endoplasmic Reticulum Membrane*The Journal of Biological Chemistry, 272
R. Storey, D. Angiolillo, Shankar Patil, Bhaloo Desai, R. Ecob, S. Husted, H. Emanuelsson, C. Cannon, R. Becker, L. Wallentin (2010)
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.Journal of the American College of Cardiology, 56 18
O. Iakoubova, M. Robertson, C. Tong, C. Rowland, J. Catanese, G. Blauw, J. Jukema, M. Murphy, J. Devlin, I. Ford, J. Shepherd (2010)
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER studyEuropean Journal of Preventive Cardiology, 17
A. Garrod (2002)
The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]The Yale Journal of Biology and Medicine, 75
F. Marín, R. González-Conejero, P. Capranzano, T. Bass, V. Roldán, D. Angiolillo (2009)
Pharmacogenetics in cardiovascular antithrombotic therapy.Journal of the American College of Cardiology, 54 12
T. Nieminen, M. Kähönen, L. Viiri, P. Grönroos, T. Lehtimäki (2008)
Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.Pharmacogenomics, 9 10
P. Borgiani, C. Ciccacci, V. Forte, S. Romano, G. Federici, G. Novelli (2007)
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.Pharmacogenomics, 8 11
T. Klein, R. Altman, N. Eriksson, B. Gage, S. Kimmel, M-T Lee, N. Limdi, D. Page, D. Roden, M. Wagner, M. Caldwell, J. Johnson (2009)
Estimation of the warfarin dose with clinical and pharmacogenetic data.The New England journal of medicine, 360 8
OA Iakoubova, M Robertson, CH Tong (2010)
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER studyEur J Cardiovasc Prev Rehabil, 17
K. Mahtani, C. Heneghan, D. Nunan, C. Bankhead, D. Keeling, A. Ward, S. Harrison, N. Roberts, F Hobbs, R. Perera (2012)
Optimal loading dose of warfarin for the initiation of oral anticoagulation.The Cochrane database of systematic reviews, 12
D. Chasman, Franco Giulianini, Jean Macfadyen, B. Barratt, F. Nyberg, P. Ridker (2012)
Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) TrialCirculation: Cardiovascular Genetics, 5
Hong-Guang Xie, H. Prasad, R. Kim, C. Stein (2002)
CYP2C9 allelic variants: ethnic distribution and functional significance.Advanced drug delivery reviews, 54 10
S. Heptinstall, J. Glenn, J. May, R. Storey, R. Wilcox (2004)
Clopidogrel resistanceCatheterization and Cardiovascular Interventions, 63
S. Rost, A. Fregin, V. Ivaškevičius, E. Conzelmann, K. Hörtnagel, H. Pelz, K. Lappegård, E. Seifried, I. Scharrer, E. Tuddenham, C. Müller, T. Strom, J. Oldenburg (2004)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 427
D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, Julia Stegherr, T. Morath, A. Schömig, N. Beckerath, A. Kastrati (2010)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent PlacementCirculation, 121
C Compton (2007)
Getting to personalized cancer medicine: taking out the garbageCancer, 110
D. Taubert, N. Beckerath, G. Grimberg, A. Lazar, Norma Jung, T. Goeser, A. Kastrati, A. Schömig, E. Schömig (2006)
Impact of P‐glycoprotein on clopidogrel absorptionClinical Pharmacology & Therapeutics, 80
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
M. Rieder, A. Reiner, B. Gage, D. Nickerson, C. Eby, H. McLeod, D. Blough, K. Thummel, D. Veenstra, A. Rettie (2005)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.The New England journal of medicine, 352 22
F. Vogel (1959)
Moderne Probleme der Humangenetik
John Thompson, Craig Hyde, Linda Wood, S. Paciga, David Hinds, David Cox, G. Hovingh, J. Kastelein (2009)
Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) CohortCirculation: Cardiovascular Genetics, 2
A. Poli (2007)
Atorvastatin: pharmacological characteristics and lipid-lowering effects.Drugs, 67 Suppl 1
E. Sconce, T. Khan, H. Wynne, P. Avery, Louise Monkhouse, B. King, P. Wood, P. Kesteven, A. Daly, F. Kamali (2005)
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood, 106 7
M. Pasanen, H. Fredrikson, P. Neuvonen, M. Niemi (2007)
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and RosuvastatinClinical Pharmacology & Therapeutics, 82
J. Verschuren, S. Trompet, J. Wessels, H. Guchelaar, M. Maat, M. Simoons, J. Jukema (2011)
Controversies in cardiovascular medicine A systematic review on pharmacogenetics in cardiovascular disease : is it ready for clinical application ?
G. Aithal, C. Day, P. Kesteven, A. Daly (1999)
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 353
L. Brunham, P. Lansberg, Lin-hua Zhang, Fudan Miao, C. Carter, G. Hovingh, H. Visscher, J. Jukema, A. Stalenhoef, C. Ross, B. Carleton, J. Kastelein, M. Hayden (2011)
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatinThe Pharmacogenomics Journal, 12
O. Iakoubova, M. Sabatine, C. Rowland, C. Tong, J. Catanese, K. Ranade, K. Simonsen, T. Kirchgessner, C. Cannon, J. Devlin, E. Braunwald (2008)
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.Journal of the American College of Cardiology, 51 4
JP Sugunaraj, C Palaniswamy, DR Selvaraj, SK Chaitanya Arudra, R Sukhija (2010)
Clopidogrel resistanceAm J Ther, 17
K. Kajinami, M. Brousseau, J. Ordovás, E. Schaefer (2005)
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.Atherosclerosis, 180 2
Kyle Ellis, G. Stouffer, H. McLeod, Craig Lee (2009)
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Pharmacogenomics, 10 11
C. Baigent, A. Keech, P. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 366
Lucio Luzzatto (1967)
Regulation of the activity of glucose-6-phosphate dehydrogenase by NADP+ and NADPH.Biochimica et biophysica acta, 146 1
J. Collet, J. Hulot, A. Pena, E. Villard, J. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, G. Montalescot (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 373
J. Brandt, S. Close, S. Iturria, C. Payne, N. Farid, C. Ernest, D. Lachno, D. Salazar, K. Winters (2007)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJournal of Thrombosis and Haemostasis, 5
(2011)
Favism A brief history from the ‘‘abstain from beans’
J. Thompson, M. Man, K. Johnson, LS Wood, M. Lira, D. Lloyd, P. Banerjee, P. Milos, SP Myrand, J. Paulauskis, M. Milad, WJ Sasiela (2005)
An association study of 43 SNPs in 16 candidate genes with atorvastatin responseThe Pharmacogenomics Journal, 5
S. Ziegler, M. Schillinger, M. Funk, Katharina Felber, M. Exner, W. Mlekusch, S. Sabeti, Jasmin Amighi, E. Minar, M. Brunner, Markus Müller, C. Mannhalter (2005)
Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery DiseaseStroke, 36
J. Mega, S. Close, S. Wiviott, Lei-Bin Shen, R. Hockett, J. Brandt, J. Walker, E. Antman, W. Macias, E. Braunwald, M. Sabatine (2009)
Cytochrome p-450 polymorphisms and response to clopidogrel.The New England journal of medicine, 360 4
C. Aquilante, T. Langaee, L. Lopez, H. Yarandi, Jennifer Tromberg, D. Mohuczy, K. Gaston, C. Waddell, M. Chirico, Julie Johnson (2006)
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirementsClinical Pharmacology & Therapeutics, 79
J. Mega, S. Close, S. Wiviott, Lei-Bin Shen, J. Walker, T. Simon, E. Antman, E. Braunwald, M. Sabatine (2010)
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisThe Lancet, 376
(1953)
Warfarin sodium derivative: (coumadin sodium); an intravenous hypoprothrombinemia-inducing agent
F. Goodsaid, S. Amur, J. Aubrecht, M. Burczynski, Kevin Carl, Jennifer Catalano, R. Charlab, S. Close, C. Cornu-Artis, L. Essioux, A. Fornace, L. Hinman, H. Hong, I. Hunt, D. Jacobson-Kram, A. Jawaid, D. Laurie, L. Lesko, Heng-Hong Li, K. Lindpaintner, J. Mayne, P. Morrow, M. Papaluca-Amati, T. Robison, John Roth, I. Schuppe-Koistinen, Leming Shi, O. Spleiss, W. Tong, S. Truter, J. Vonderscher, A. Westelinck, Li Zhang, I. Zineh (2010)
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impactNature Reviews Drug Discovery, 9
Emma Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop, R. Collins (2008)
SLCO1B1 variants and statin-induced myopathy--a genomewide study.The New England journal of medicine, 359 8
T. Cuisset, P. Morange, M. Alessi (2011)
Recent advances in the pharmacogenetics of clopidogrelHuman Genetics, 131
O. Iakoubova, C. Tong, C. Rowland, T. Kirchgessner, Bradford Young, A. Arellano, D. Shiffman, M. Sabatine, H. Campos, C. Packard, M. Pfeffer, T. White, E. Braunwald, J. Shepherd, J. Devlin, F. Sacks (2008)
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.Journal of the American College of Cardiology, 51 4
D. Mukherjee, E. Topol (2003)
Pharmacogenomics in cardiovascular diseases.Progress in cardiovascular diseases, 44 6
A. Motulsky (1957)
Drug reactions enzymes, and biochemical genetics.Journal of the American Medical Association, 165 7
J. Larosa, Jiang He, S. Vupputuri (1999)
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.JAMA, 282 24
J. Hulot, J. Collet, G. Montalescot (2011)
Genetic substudy of the PLATO trialThe Lancet, 377
M. Barber, L. Mangravite, C. Hyde, D. Chasman, Joshua Smith, C. McCarty, Xiaohui Li, R. Wilke, M. Rieder, Paul Williams, P. Ridker, A. Chatterjee, J. Rotter, D. Nickerson, M. Stephens, R. Krauss (2010)
Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study PopulationsPLoS ONE, 5
L. Kaminsky, Zhi-Yi Zhang (1997)
Human P450 metabolism of warfarin.Pharmacology & therapeutics, 73 1
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, D. Scott, A. Gunes, M. Dahl (2008)
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.JACC. Cardiovascular interventions, 1 6
J. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, C. Goyenvalle, M. Aiach, P. Lechat, P. Gaussem (2006)
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood, 108 7
T. Cuisset, C. Frère, J. Quilici, P. Morange, N. Saut, M. Lambert, L. Camoin, I. Vague, J. Bonnet, M. Alessi (2007)
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.Thrombosis research, 120 6
W. Ageno, L. Steidl, C. Ultori, F. Dentali, C. Marchesi, Valentina Mera, A. Squizzato, A. Venco (2003)
The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosisBlood Coagulation & Fibrinolysis, 14
D. Voora, H. McLeod, C. Eby, B. Gage (2005)
The pharmacogenetics of coumarin therapy.Pharmacogenomics, 6 5
(2011)
Cytochrome 2 C 19 * 17 Allelic Variant , Platelet Aggregation , Bleeding Events , and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
L. Goodman, A. Gilman, R. Hilal-Dandan, L. Brunton (2007)
Goodman and Gilman's Manual of Pharmacology and Therapeutics
M. Wadelius, Leslie Chen, K. Downes, J. Ghori, S. Hunt, N. Eriksson, O. Wallerman, H. Melhus, C. Wadelius, D. Bentley, P. Deloukas (2005)
Common VKORC1 and GGCX polymorphisms associated with warfarin doseThe Pharmacogenomics Journal, 5
J. Carlquist, B. Horne, J. Muhlestein, D. Lappé, Bryant Whiting, Matthew Kolek, Jessica Clarke, Brent James, Jeffrey Anderson (2006)
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective studyJournal of Thrombosis and Thrombolysis, 22
M. Niemi, M. Pasanen, P. Neuvonen (2006)
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatinClinical Pharmacology & Therapeutics, 80
Garrod Ae (1975)
The Lancet. The incidence of alkaptonuria: a study in chemical individuality.Nutrition Reviews, 33
B. Giusti, A. Gori, R. Marcucci, C. Saracini, I. Sestini, R. Paniccia, S. Valente, D. Antoniucci, R. Abbate, G. Gensini (2007)
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsPharmacogenetics and Genomics, 17
L. Wallentin, S. James, R. Storey, M. Armstrong, Bryan Barratt, J. Horrow, S. Husted, H. Katus, P. Steg, P. Steg, Svati Shah, Richard Becker (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 376
H. Furuya, P. Fernández-Salguero, W. Gregory, H. Taber, Annette Steward, F. Gonzalez, J. Idle (1995)
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.Pharmacogenetics, 5 6
J Meletis (2011)
Favism A brief history from the “abstain from beans” of Pythagoras to the presentArch Hellenic Med, 11
P. Ridker, Jean Macfadyen, R. Glynn, D. Chasman (2011)
Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary PreventionCirculation: Cardiovascular Genetics, 4
Jeffrey Anderson, B. Horne, S. Stevens, S. Woller, Kent Samuelson, Justin Mansfield, Michelle Robinson, S. Barton, Kimberly Brunisholz, Chrissa Mower, John Huntinghouse, Jeffrey Rollo, Dustin Siler, T. Bair, S. Knight, J. Muhlestein, J. Carlquist (2012)
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)Circulation, 125
N. Ford (2009)
Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?The Journal of Clinical Pharmacology, 49
M. Caldwell, R. Berg, K. Zhang, I. Glurich, J. Schmelzer, S. Yale, H. Vidaillet, J. Burmester (2007)
Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 5
G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, E. Romagnoli, G. Sangiorgi, D. Angiolillo, M. Valgimigli, L. Testa, F. Gaita, I. Sheiban (2011)
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.International journal of cardiology, 150 3
M. Law, A. Rudnicka (2006)
Statin safety: a systematic review.The American journal of cardiology, 97 8A
JJ Verschuren, S Trompet, JA Wessels, HJ Guchelaar, MP Maat, ML Simoons, JW Jukema (2011)
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Eur Heart J, 33
Juan Pedro-Botet, Juan Pedro-Botet, E. Schaefer, E. Schaefer, R. Bakker-Arkema, Donald Black, Evan Stein, Dolores Corella, J. Ordovás, J. Ordovás (2001)
Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Atherosclerosis, 158 1
In the coming years, genomics will impact clinical practice in multiple ways. However, one of the most important applications will be in the determination of the best treatments in personalized medicine. This is, in fact, one of the fields in which genetic variants have already been most successful and useful to clinicians. Here, we briefly review the current state of the art on pharmacogenomics and its applications to modern cardiovascular medicine.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Mar 29, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.